Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.
Stolearenco V, Levring TB, Nielsen HM, Lindahl L, Fredholm S, Kongsbak-Wismann M, Willerslev-Olsen A, Buus TB, Nastasi C, Hu T, Gluud M, Côme CRM, Krejsgaard T, Iversen L, Bonefeld CM, Grønbæk K, Met Ö, Woetmann A, Ødum N, Geisler C. Stolearenco V, et al. Among authors: met o. Dermatology. 2021;237(2):283-290. doi: 10.1159/000509159. Epub 2020 Aug 14. Dermatology. 2021. PMID: 32799209
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH. Ahmad SM, et al. Among authors: met o. Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. Oncoimmunology. 2017. PMID: 29308318 Free PMC article.
SATB1 in Malignant T Cells.
Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N. Fredholm S, et al. Among authors: met o. J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8. J Invest Dermatol. 2018. PMID: 29751003 Free article.
Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome.
Hu T, Buus TB, Krejsgaard T, Nansen A, Lundholt BK, Spee P, Fredholm S, Petersen DL, Blümel E, Gluud M, Monteiro MN, Willerslev-Olsen A, Andersen MH, Straten PT, Met Ö, Stolearenco V, Fogh H, Gniadecki R, Nastasi C, Litman T, Woetmann A, Gjerdrum LMR, Ødum N. Hu T, et al. Among authors: met o. Oncotarget. 2019 Aug 6;10(47):4894-4906. doi: 10.18632/oncotarget.27122. eCollection 2019 Aug 6. Oncotarget. 2019. PMID: 31448055 Free PMC article.
Inflammation induced PD-L1-specific T cells.
Munir S, Lundsager MT, Jørgensen MA, Hansen M, Petersen TH, Bonefeld CM, Friese C, Met Ö, Straten PT, Andersen MH. Munir S, et al. Among authors: met o. Cell Stress. 2019 Sep 13;3(10):319-327. doi: 10.15698/cst2019.10.201. Cell Stress. 2019. PMID: 31656949 Free PMC article.
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Weis-Banke SE, Hübbe ML, Holmström MO, Jørgensen MA, Bendtsen SK, Martinenaite E, Carretta M, Svane IM, Ødum N, Pedersen AW, Met Ö, Madsen DH, Andersen MH. Weis-Banke SE, et al. Among authors: met o. Oncoimmunology. 2020 Jun 1;9(1):1771142. doi: 10.1080/2162402X.2020.1771142. Oncoimmunology. 2020. PMID: 32923127 Free PMC article.
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Bendtsen SK, Perez-Penco M, Hübbe ML, Martinenaite E, Orebo Holmström M, Weis-Banke SE, Grønne Dahlager Jørgensen N, Jørgensen MA, Munir Ahmad S, Jensen KM, Friese C, Lundsager MT, Johansen AZ, Carretta M, Ødum N, Met Ö, Svane IM, Madsen DH, Andersen MH. Bendtsen SK, et al. Among authors: met o. Oncoimmunology. 2022 Jan 27;11(1):2026020. doi: 10.1080/2162402X.2022.2026020. eCollection 2022. Oncoimmunology. 2022. PMID: 35111385 Free PMC article.
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE, Lisle TL, Perez-Penco M, Schina A, Hübbe ML, Siersbæk M, Holmström MO, Jørgensen MA, Marie Svane I, Met Ö, Ødum N, Madsen DH, Donia M, Grøntved L, Andersen MH. Weis-Banke SE, et al. Among authors: met o. J Immunother Cancer. 2022 Oct;10(10):e005326. doi: 10.1136/jitc-2022-005326. J Immunother Cancer. 2022. PMID: 36316062 Free PMC article.
83 results